

6 May 2026

Appointment of Executive Director

Highlights:

- **Andrew Chapman appointed Executive Director to lead corporate strategy and public market execution**
- **Roby Zomer transitions to Non-Executive Chairman, focusing on U.S. strategy and growth initiatives**
- **Board transition follows completion of the acquisition of AusCann's 48% interest in CannPal**

Argent BioPharma Ltd (ASX: RGT) (Argent or the Company) is pleased to announce a series of Board and leadership changes following the successful completion of the acquisition of AusCann Group Holdings Limited's 48% interest in CannPal Animal Therapeutics Pty Ltd¹ (**CannPal**). This transition marks the Company's progression into a new strategic phase, focused on consolidating a high-value, IP-driven neuro-immune portfolio and positioning the business for potential U.S. public market expansion. The updated leadership structure is designed to strengthen corporate execution, capital markets readiness, and long-term growth strategy.

Appointment of Andrew Chapman as Executive Director

Mr Andrew Chapman has been appointed as Executive Director of Argent BioPharma. Mr Chapman brings extensive experience across public markets, corporate strategy, and life sciences transactions, including his previous leadership roles within ASX-listed companies and involvement in the development and commercialisation of pharmaceutical and EU-GMP manufacturing assets.

Mr Chapman has Graduate and Post Graduate qualifications in Business, Finance and Hospitality. He established Merchant Group in 2011, after spending 9 years with one of Perth's leading private wealth managers.


In his role, Mr Chapman will lead the Company's corporate strategy, capital markets positioning, and public company execution as Argent BioPharma advances toward its next phase of growth.

Transition of Roby Zomer to Chairman

Following this appointment, Mr Roby Zomer will transition from his executive role to Non-Executive Chairman of the Board.

In this capacity, Mr Zomer will continue to support the Company's strategic direction, with a particular focus on U.S. market strategy, capital formation, and the development of non-pharmaceutical initiatives aligned with the Company's broader growth objectives.

¹ Refer to ASX Announcement dated 14 January 2026



Board Departure

Mr Gary Hermon will step down from the Board as part of this transition. The Company thanks Mr Hermon for his contribution and service during his tenure and wishes him well in his future endeavours.

Strategic Direction

These changes reflect the Company's transition into its next phase following the CannPal acquisition, with a strengthened focus on:

- Building a coherent and IP-driven asset portfolio
- Advancing corporate strategy and capital markets readiness
- Positioning the Company for a potential U.S. national exchange listing

The combination of Mr Chapman's corporate and capital markets expertise, alongside Mr Zomer's continued strategic involvement, is expected to provide a clear leadership structure aligned with these objectives.

Andrew Chapman, Executive Director, commented:

"I am pleased to join Argent BioPharma at an important stage in its development. The Company has established a differentiated asset base across neurological and immune-related indications, and I look forward to supporting its corporate strategy and market positioning as it advances toward its next phase of growth."

Roby Zomer, Chairman, commented:

"This transition reflects the natural progression of Argent BioPharma following the completion of the CannPal acquisition. With Andrew leading the Company's corporate and capital markets strategy, we are strengthening our leadership structure to support the next phase of growth. I remain closely involved in shaping our U.S. strategy and broader development initiatives as we continue to build a focused, IP-driven platform."

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma

Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma


Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead assets, CannEpi[®] and CimetrA[®], are being advanced for drug-resistant epilepsy and inflammatory conditions, respectively. The Company leverages proprietary nano-delivery technologies designed to optimise bioavailability and tissue penetration, including across the blood-brain barrier and pulmonary interfaces. With vertically integrated EU-GMP manufacturing, a unified Neuro-Immune Modulatory platform, and ongoing clinical development programs, Argent BioPharma is advancing a focused pipeline targeting central nervous system and systemic inflammatory conditions with significant unmet medical need

Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com





Appendix 1

Key Terms of Employment of Executive Director

Term	Ongoing until terminated by either party in accordance with the Employment Agreement.
Remuneration	Fixed monthly remuneration of US\$8,000 per month.
Termination	The Company may terminate employment without cause at any time by providing 3 months' notice or without notice in certain circumstances including serious misconduct or breach of the employment agreement. Mr Chapman may resign at any time by providing 3 months' notice.
Other provisions	Customary provisions, including roles and responsibilities, leave entitlements, reimbursement of expenses, confidentiality obligations and ancillary provisions.

Key Terms of Employment of Chairman

Term	Ongoing until terminated by either party in accordance with the Employment Agreement.
Remuneration	Fixed monthly cash remuneration of US\$8,000 per month and a monthly fee of US\$5,000, to be satisfied by the issue of fully paid ordinary shares, priced at the 20-day VWAP of the Company's shares traded on the ASX, with shares to be issued annually subject to shareholder approval at the Company's Annual General Meeting.
Termination	The Company may terminate employment without cause at any time by providing 12 months' notice or without notice in certain circumstances including serious misconduct or breach of the employment agreement.
Other provisions	Customary provisions, including roles and responsibilities, leave entitlements, reimbursement of expenses, confidentiality obligations and ancillary provisions.

